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ABSTRACT
Background Moderately raised serum bilirubin 
levels are associated with lower rates of lung cancer, 
particularly among smokers. It is not known whether 
these relationships reflect antioxidant properties or 
residual confounding.
Objective This study aimed to investigate potential 
causal relationships between serum total bilirubin and 
lung cancer incidence using one- sample Mendelian 
randomisation (MR) and UK Biobank.
Methods We instrumented serum total bilirubin level 
using two variants (rs887829 and rs4149056) that 
together explain ~40% of population- level variability 
and are linked to mild hereditary hyperbilirubinaemia. 
Lung cancer events occurring after recruitment were 
identified from national cancer registries. Observational 
and genetically instrumented incidence rate ratios (IRRs) 
and rate differences per 10 000 person- years (PYs) by 
smoking status were estimated.
Results We included 377 294 participants (median 
bilirubin 8.1 μmol/L (IQR 6.4–10.4)) and 2002 lung 
cancer events in the MR analysis. Each 5 μmol/L 
increase in observed bilirubin levels was associated with 
1.2/10 000 PY decrease (95% CI 0.7 to 1.8) in lung 
cancer incidence. The corresponding MR estimate was 
a decrease of 0.8/10 000 PY (95% CI 0.1 to 1.4). The 
strongest associations were in current smokers where 
a 5 μmol/L increase in observed bilirubin levels was 
associated with a decrease in lung cancer incidence 
of 10.2/10 000 PY (95% CI 5.5 to 15.0) and an MR 
estimate of 6.4/10 000 PY (95% CI 1.4 to 11.5). For 
heavy smokers (≥20/day), the MR estimate was an 
incidence decrease of 23.1/10 000 PY (95% CI 7.3 to 
38.9). There was no association in never smokers and no 
mediation by respiratory function.
Conclusion Genetically raised serum bilirubin, common 
across human populations, may protect people exposed 
to high levels of smoke oxidants against lung cancers.
INTRODUCTION
Lung cancer is the leading cause of cancer death 
globally due to the high incidence and poor prog-
nosis.1 Risk assessment for lung cancer in primary 
care settings relies on self- reported smoking 
status, which can be challenging to quantify 
accurately. Identifying simple blood biomarkers 
for lung cancer, comparable with cholesterol in 
cardiovascular disease, could improve the cost- 
effectiveness of new screening programmes2 and 
potentially lead to new treatments for oxidative 
stress- mediated diseases.
Following the natural death of red blood 
cells, a series of reactions initiated by the haem 
oxygenase enzymes one and two (HMOX1/
HMOX2) generates the yellow pigment bilirubin. 
At first, bilirubin is water insoluble and is trans-
ported in the blood serum to the liver where it 
is converted to a soluble (conjugated) form for 
elimination by the enzyme uridine diphosphate- 
glucuronosyltransferase 1–1 (UGT1A1). Bili-
rubin levels are frequently tested in primary 
healthcare settings to assess liver function and 
guide prescribing decisions for drugs including 
statins. Various lines of evidence, such as the high 
frequency of UGT1A1 alleles causing mild hered-
itary hyperbilirubinaemia (Gilbert’s syndrome; 
OMIM#143500), has led to speculation that 
moderately raised levels may have a physiological 
benefit for humans.3–5 Investigations using blood 
serum, tissue cultures and animal models suggest 
that bilirubin has potent antioxidant properties 
that may help protect respiratory tissues against 
oxidative stress.5–8 For example, the enzymes that 
generate bilirubin (biliverdin reductase, HMOX1) 
are found at their highest concentrations in respi-
ratory tissues 9 and a recent network analysis of 
the effect of cigarette smoke on the lung tissue 
Key messages
What is the key question?
 ► Is there evidence that moderately raised serum 
bilirubin, a purported antioxidant, can protect 
against lung cancer and does the relationship 
differ according to smoking status?
What is the bottom line?
 ► Current and former cigarette smokers 
genetically predisposed to raised levels of 
serum total bilirubin have lower rates of lung 
cancer with the association strongest in current 
heavy smokers. There was no relationship 
between genetically instrumented or observed 
bilirubin levels for never smokers.
Why read on?
 ► This is the first study to support a potential 
causal association between serum bilirubin 
and the incidence of lung cancer in cigarette 
smokers.
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of mice identified dramatic increases in bilirubin production 
implying a protective role.10 Population- based cohort studies 
have also linked moderately raised serum bilirubin levels with 
lower rates of respiratory diseases and lung cancer with the 
strongest associations in cigarette smokers.11–14 Although 
these observations are consistent with an endogenous antioxi-
dant function for bilirubin, the relationships with lung cancer 
could reflect residual confounding or reverse causation. For 
instance, liver diseases, infections, acute events such as heart 
attacks, certain drugs and environmental exposures can influ-
ence bilirubin levels.11 15 16
Mendelian randomisation (MR) is an approach that, with 
important assumptions, could address certain limitations of 
observational studies of bilirubin and provide more robust 
support of a causal mechanism.17 First, the random allocation 
of alleles during gamete formation and conception should 
balance observed and unobserved confounders across genetic 
groups. Second, genotype status is unaffected by disease 
processes and reverse causation is unlikely. Finally, geno-
typing is less prone to random error and regression dilution 
bias. Here, we present a large- scale MR examining the rela-
tionship between genetically raised serum bilirubin and lung 
cancer in adults participating in UK Biobank. We also report 
the cross- sectional associations between bilirubin and respira-
tory function as a potential mediator of the relationship with 
lung cancer.
Table 1 Baseline characteristics of UK Biobank participants by sex- specific quintiles of serum bilirubin levels
Covariates Total Sex- specific quintile categories of serum total bilirubin (μmol/L) P value* Missing data (%)
Women   1.1 5.6 6.7 7.9 9.8–41
Men   1.1 6.7 8.4 10.0 12.5–41
  N=357 802 N=71 230 N=71 514 N=71 793 N=71 580 N=71 685
Sex 165 817 (46.3%) 33 089 (46.5%) 33 057 (46.2%) 33 205 (46.3%) 33 241 (46.4%) 33 225 (46.3%)
Age at recruitment (IQR) 58.9 (51.4–64.0) 58.3 (51.1–63.7) 59.2 (51.8–64.0) 59.3 (51.9–64.1) 59.2 (51.5–64.1) 58.5 (50.5–63.9) <0.0001
Weight (kg) 78.3 (15.9) 79.7 (16.4) 78.8 (15.9) 78.3 (15.7) 77.7 (15.6) 77.3 (15.5) <0.0001 986 (0.3)
Height (cm) 168.8 (9.2) 167.9 (9.2) 168.5 (9.2) 168.9 (9.2) 169.2 (9.2) 169.6 (9.2) <0.0001 714 (0.2)
BMI 27.4 (4.7) 28.2 (5.1) 27.7 (4.8) 27.4 (4.7) 27.1 (4.6) 26.8 (4.5) <0.0001 1107 (0.3)
Waist circumference (cm) 90.4 (13.5) 92.4 (13.7) 91.0 (13.4) 90.3 (13.3) 89.5 (13.3) 88.8 (13.3) <0.0001 576 (0.2)
Smoking status             <0.0001
  Never 194 558 (54.4%) 34 687 (48.7%) 38 066 (53.2%) 39 326 (54.8%) 40 390 (56.4%) 42 089 (58.7%)
  Former 125 965 (35.2%) 24 529 (34.4%) 25 115 (35.1%) 25 746 (35.9%) 25 554 (35.7%) 25 021 (34.9%)
  Current 36 059 (10.1%) 11 739 (16.5%) 8089 (11.3%) 6490 (9.0%) 5382 (7.5%) 4359 (6.1%)
  Prefer not to say 1220 (0.3%) 275 (0.4%) 244 (0.3%) 231 (0.3%) 254 (0.4%) 216 (0.3%)
Pack years of smoking 
(IQR)†
19.5 (10.0–32.5) 22.8 (12.2–36.0) 20.2 (10.5–33.5) 18.8 (9.8–31.9) 18.0 (9.0–30.5) 16.5 (8.6–28.5) <0.0001
Occupational smoke 
exposure
94 720 (26.5%) 22 933 (32.2%) 19 566 (27.4%) 18 262 (25.4%) 17 343 (24.2%) 16 616 (23.2%) <0.0001
Exposure to smoke at 
home
32 620 (9.1%) 6707 (9.4%) 6546 (9.2%) 6494 (9.0%) 6404 (8.9%) 6469 (9.0%) 0.002
Antioxidant supplements 97 340 (27.2%) 19 770 (27.8%) 19 595 (27.4%) 19 510 (27.2%) 19 477 (27.2%) 18 988 (26.5%) <0.0001
Nitrogen dioxide air 
pollution (µg/m3); 2010 
(IQR)
25.6 (21.0–30.4) 25.9 (21.3–30.6) 25.5 (21.0–30.4) 25.4 (20.9–30.3) 25.4 (20.9–30.3) 25.4 (20.8–30.3) <0.0001 4817 (1.4)
Particulate matter 
air pollution (µg/m3) 
(PM2.5); 2010 (IQR)
9.88 (9.23,10.49) 9.93 (9.28,10.54) 9.89 (9.23,10.50) 9.86 (9.21,10.48) 9.86 (9.21,10.48) 9.85 (9.20,10.46) <0.0001 30 282 (8.5)
Townsend deprivation 
index (IQR)
−2.4 (−3.7–0.1) −2.1 (−v3.6–0.6) −2.3 (−3.7–0.1) −2.4 (−3.8 to -0.1) −2.4 (−3.8 to -0.2) −2.5 (−3.8 to -0.2) <0.0001 431 (0.1)
History of lung cancer 527 (0.15%) 152 (0.21%) 115 (0.16%) 85 (0.12%) 99 (0.14%) 76 (0.11%) <0.0001
Family history of lung 
cancer
46 093 (12.9%) 9510 (13.4%) 9374 (13.1%) 9157 (12.8%) 9167 (12.8%) 8885 (12.4%)
History of COPD/
emphysema
8129 (2.3%) 2106 (3.0%) 1736 (2.4%) 1487 (2.1%) 1506 (2.1%) 1294 (1.8%) <0.0001
FEV1 (L) 2.9 (0.8) 2.8 (0.8) 2.8 (0.8) 2.9 (0.8) 2.9 (0.8) 2.9 (0.8) <0.0001 86 032 (24)
FEV1 (L) ATS/ERS 
reproducibility
2.8 (0.7) 2.7 (0.7) 2.8 (0.7) 2.8 (0.7) 2.8 (0.7) 2.9 (0.7) <0.0001 144 935 (41)
Lung cancer events 1917 548 418 356 328 267
Person years (10 000) 252 50 50 50 51 50
Incidence rate per 10 000 
(95% CI)
7.6 (7.3–8.0) 10.9 (10.1–11.9) 8.3 (7.5–9.1) 7.1 (6.4–7.9) 6.5 (5.8–7.2) 5.3 (4.7–6.0) <0.0001‡
All continuous variables are mean values with ±1 standard or medians for skewed data if IQRs are specified.
*P values for sex- adjusted associations with log- transformed serum total bilirubin levels as the dependent variable.
†Previously calculated for 109 312 participants reporting to regularly smoke at least 1 cigarette/day and who also reported smoking duration.
‡Poisson model with lung cancer incidence as the dependent variable adjusted for sex.
ATS/ERS, Reproducibility of spirometry measurement using American Thoracic Society (ATS) and European Respiratory Society (ERS); BMI, body mass index; PYs, person- years.
2 Horsfall LJ, et al. Thorax 2020;0:1–10. doi:10.1136/thoraxjnl-2020-214756
Lung cancer
METHODS
Data source
The UK Biobank Resource is a prospective cohort study of over 
500 000 participants aged 40–69 years and recruited between 
2006 and 2010 from different regions of the UK.18 Further infor-
mation on UK Biobank is provided in the online supplementary 
methods and at the website (https://www. ukbiobank. ac. uk/).
Study design
Initially, to verify previous studies, we analysed the observational 
relationship between serum total bilirubin levels measured at base-
line and incident lung cancer. We also examined the cross- sectional 
relationship between observed serum bilirubin and FEV1. Second, 
using MR approach, we estimated the potential causal relation-
ships between bilirubin levels and these outcomes using individual- 
level data. The study protocol was approved by UK Biobank in July 
2018 (ID: 5167) and adequacy of sample size was checked using 
online tools (http:// cnsgenomics. com/ shiny/ mRnd/).
Inclusion/exclusion criteria
After excluding people no longer wishing to participate, the total 
number of participants available for analysis was 502 527. We 
applied several genetic exclusions including those recommended 
by UK Biobank, outliers for genotype missingness or excess 
heterozygosity, sex aneuploidy and sex discordance (n=2200). 
We used a published algorithm to retain unrelated participants19 
(n=39 642) and finally restricted the sample to ‘white British’ 
participants using a combination of self- reported ethnic identity 
and the results of an existing principal components analysis avail-
able in the dataset (n=88 341).20 Participants entered the cohort 
on the date they attended the research centre and were censored 
at the earliest date of lung cancer diagnosis, loss to follow- up, 
Figure 1 Margins of response by smoking status as adjusted lung cancer incidence rates with 95% CIs (shaded) at different levels of observed 
bilirubin (panels A and B) and genetically predicted bilirubin (panels C and D) while holding all other variables at their observed values. Variables 
included age, gender, calendar year, ethnicity (first 40 principal components) and recruitment centre. Predictions for observed bilirubin also include 
height and weight. Non- linear relationships were captured using cubic spline transformation with three knots placed at the 10th, 50th and 90th 
percentiles of bilirubin levels. Values with 95%CIs are reported in online supplementary table S3.
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death or end of the follow- up period. The most recent date of 
complete monitoring for incident cancers at the time of anal-
ysis was 31 March 2016 for England and Wales and 31 October 
2015 for Scotland. Participants with a history of lung cancer at 
the time of recruitment were excluded from the primary analysis 
of lung cancer incidence (n=527).
Exposures
Blood samples were collected at baseline from all participants, 
and serum total bilirubin was assayed by photometric colour 
(Beckman Coulter AU5800). Genome- wide association studies 
(GWAS) have repeatedly identified UGT1A1 at 2q37 as the 
major locus underlying serum bilirubin levels across human 
Table 2 Observational relationships between mean serum total bilirubin and lung cancer incidence by smoking status in white British unrelated 
participants in UK Biobank
Lung cancer 
events
PYs
(10 000)
Lung cancer incidence 
rate per 10 000 PYs 
(95% CI)
Adjusted IRR per 5 
μmol/L increase (95% 
CI)* P value
Predicted incidence change in 
10 000 PYs per 5 μmol/L increase 
(95% CI) *
Overall 1901 251 7.6 (7.2 to 7.9) 0.85 (0.80 to 0.92) <0.0001 −1.2 (−1.8 to −0.7)
Never smokers 261 137 1.9 (1.7 to 2.1) 1.00 (0.87 to 1.15) 0.97 0.01 (−0.3 to 0.3)
Former smokers 888 88 10.1 (9.5 to 10.8) 0.87 (0.79 to 0.96) 0.0037 −1.2 (−2.1 to −0.4)
Current smokers 743 25 29.7 (27.6 to 31.9) 0.74 (0.63 to 0.86) <0.0001 −10.2 (−15.0 to −5.5)
Prefer not to report 9 1 10.8 (5.6 to 20.7)
Regular smokers (cigarettes per day) †
  Overall 1422 75 18.9 (17.9 to 19.9) 0.77 (0.70 to 0.84) <0.0001 −5.0 (−6.8 to −3.2)
  Former 1–19 187 24 7.7 (6.7 to 8.9) 0.95 (0.80 to 1.12) 0.52 −0.4 (−1.7 to 0.8)
  Former ≥20 554 32 17.5 (16.1 to 19.0) 0.79 (0.69 to 0.90) 0.0006 −3.7 (−5.9 to −1.6)
  Current 1–19 285 11 27.0 (24.0 to 30.3) 0.88 (0.70 to 1.13) 0.32 −4.2 (−12.3 to 3.9)
  Current ≥20 341 7 51.7 (46.5 to 57.5) 0.76 (0.60 to 0.95) 0.021 −18.4 (−33.3 to −3.4)
*Adjusted for age, gender, calendar year, ethnicity (first 40 principal components), height, weight, recruitment centre and smoking status. Adjusted and unadjusted incidence rate 
ratios are reported in online supplementary table 1.
†Adjusted for pack- years, age, gender, calendar year, ethnicity (first 40 principal components), height, weight, recruitment centre. Participants currently smoking less than one 
cigarette per day at recruitment are excluded from the smoking subcategories but included in the overall analysis of regular smokers if they had formerly smoked one or more 
per day and it was possible to calculate pack- years.
IRR, incidence rate ratio; PYs, person- years.
Figure 2 Nelson- Aalen estimate of the cumulative hazard function for the UGT1A1 rs887829 genotype and lung cancer by smoking status.
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populations.21–23 A GWAS of British subjects found the single 
nucleotide polymorphism (SNP) rs887829 explained 39%–43% 
of the variation in bilirubin levels.24 This SNP is in almost 
complete linkage disequilibrium (r2=0.99) with the functional 
repeat- length polymorphism of the UGT1A1 promoter region 
underlying Gilbert’s syndrome.3 25 Bilirubin GWAS have consis-
tently replicated another signal at 12p12.22 25 26 The nonsynony-
mous SNP rs4149056 (Val174Ala) of the Solute Carrier Organic 
Anion Transporter Family Member 1B1 (SLCO1B1) is a lead 
causal SNP in this region and transports bilirubin from blood 
into the liver. Both rs887829 and rs4149056 were included on 
the microarrays and we used these variants to instrument bili-
rubin levels. Missing genotypes were replaced with imputed data 
where available.20 Based on known substrates for these enzymes 
and searches of online GWAS repositories, we did not expect 
any important confounding of the genetic relationships by other 
mechanisms (pleiotropy).
Outcomes
The primary outcome is incident lung cancer recorded following 
study recruitment. Prevalent and incident cancer diagnoses in UK 
Biobank are provided by The Health & Social Care Information 
Centre for participants residing in England and Wales, and the 
NHS Central Register for participants residing in Scotland. These 
national cancer registries obtain information from a range of 
sources including hospitals, treatment centres, hospices and nursing 
homes, private hospitals, general practices, death certificates and 
Hospital Episode Statistics. Underlying (primary) cause of death is 
also provided from central registers. Diagnoses and causes of death 
Table 3 Genotype frequency and association with serum bilirubin levels and crude lung cancer incidence rates for SNPs used in genetic 
instrumentation
SNP Number (%)
Median serum 
total bilirubin 
(μmol/L) (IQR)
Lung 
cancer 
events
Lung cancer incidence per 10 000 PYs (95% CI)
Overall Never smokers Former smokers Current smokers
UGT1A1 rs887829 R2=37%
CC 177 209 (47.0) 7.2 (5.9–8.8) 960 7.7 (7.2 to 8.2) 1.9 (1.6 to 2.3) 10.3 (9.4 to 11.3) 30.2 (27.3 to 33.4)
CT 162 815 (43.2) 8.5 (6.9–10.6) 875 7.7 (7.2 to 8.1) 1.9 (1.6 to 2.3) 9.8 (8.9 to 10.8) 31.3 (28.2 to 34.7)
TT 37 270 (9.9) 15.7 (12.0–20.3) 167 6.4 (5.5 to 7.4) 1.8 (1.2 to 2.7) 9.4 (7.6 to 11.6) 21.4 (16.5 to 27.8)
  p value* <0.0001         
SLCO1B1 rs4149056   R2=1%         
TT 272 515 (72.2) 7.9 (6.3–10.2) 1458 7.6 (7.2 to 8.2) 1.8 (1.6 to 2.1) 10.2 (9.4 to 11) 30.1 (27.8 to 32.7)
TC 96 153 (25.5) 8.5 (6.7–10.9) 497 7.4 (6.7 to 8.0) 2.1 (1.6 to 2.6) 9.3 (8.2 to 10.6) 29.4 (25.6 to 33.8)
CC 8626 (2.3) 9.1 (7.3–11.6) 47 7.8 (5.8 to 10.3) 1.5 (0.6 to 3.7) 12.1 (8.2 to 17.8) 24.4 (14.7 to 40.6)
  p value* <0.0001         
*Kruskal- Wallis test.
PYs, person- years; SNP, single nucleotide polymorphism.
Table 4 Lung cancer incidence by UGT1A1 rs887829 genotype and smoking status reported on the ratio and rate difference scales
UGT1A1 rs887829/smoking 
status*
Lung cancer incidence per 
10 000 PYs (95% CI) IRR (95% CI)*
P value* for within 
smoking comparison
Lung cancer predicted 
incidence difference 
per 10 000 person years 
(95% CI)†
P value† for 
within smoking 
comparison
TT/never 1.8 (1.2 to 2.7) 1.0 (ref) Ref Ref
CC or CT/never 1.9 (1.7 to 2.2) 1.1 (0.7 to 1.6) 0.82 0.1 (−0.6 to 0.8) 0.81
TT/former 9.4 (7.5 to 11.6) 4.2 (2.7 to 6.5) Ref Ref
CC or CT/former 10.1 (9.4 to 10.8) 4.5 (3.2 to 6.7) 0.54 0.60 (−1.2 to 2.4) 0.54
TT/current 21.4 (16.5 to 27.8) 12.8 (8.0 to 20.4) Ref Ref
CC or CT/current 30.1 (28.6 to 33.1) 18.6 (12.6 to 27.6) 0.0076 11.1 (4.1 to 18.1) 0.0019
Regular smokers (cigarettes per day)†       
TT/former 1–19 8.2 (5.4 to 12.6) 1.0 (ref) Ref   
CC or CT/ former 1–19 7.7 (6.7 to 8.9) 0.9 (0.6 to 1.5) 0.78 −0.5 (−4.0 to 3.1) 0.79
TT/former ≥20 14.9 (11.3 to 19.7) 1.7 (1.0 to 2.9) Ref   
CC or CT/former ≥20 17.4 (16 to 18.9) 2.0 (1.3 to 3.1) 0.33 2.0 (−2.0 to 6.2) 0.31
TT/current 1–19 24.7 (17.1 to 35.8) 4.1 (2.3 to 7.1) Ref   
CC or CT/ current 1–19 27.3 (24.3 to 30.8) 4.5 (2.9 to 7.0) 0.60 3.6 (−9.0 to 16.1) 0.58
TT/current ≥20 26.8 (16.9 to 42.5) 4.5 (2.4 to 8.4) Ref   
CC or CT/current ≥20 54.9 (49.5 to 61) 9.4 (6 to 14.6) 0.0023 38.7 (20.6 to 56.9) <0.0001
*Rate ratios on the multiplicative (relative) scale and adjusted for age, gender, calendar year, ethnicity (first 40 principal components) and recruitment centre.
†Marginal effect on the additive (incidence) scale and adjusted for age, gender, calendar year, ethnicity (first 40 principal components) and recruitment centre.
IRR, incidence rate ratio; PYs, person- years.
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are coded using the International Classification of Disease (ICD) 
version 9 and 10. Malignant neoplasms of the trachea and bron-
chus (ICD10: C33- C34) are the cancers where smoking has the 
strongest pathophysiological role and highest attributable risk at 
>70%, and we selected these cancers as our primary outcome.27 A 
self- reported cancer diagnosis is also available and used in addition 
to ICD codes to identify participants’ cancer history.
Other risk factors for lung cancer including FEV1 and family 
history of lung cancer, and comorbidity for COPD or emphysema 
are potentially on the causal pathway between bilirubin antioxi-
dant activity and lung cancer. We therefore examined these sepa-
rately as secondary outcomes in a series of cross- sectional analyses 
(online supplementary methods). Oxidative stress is thought to 
have a pathophysiological role in many age- related diseases, and as 
further supplemental analyses, we also explored relationships with 
mortality from any cause and cancer mortality.
Covariates
Basic characteristics and known predictors of lung cancer were 
included in analyses to improve the precision of the estimates.17 28 
Depending on the outcome, these included age, calendar year, 
genetic sex, recruitment centre, height, weight and self- reported 
smoking status. We also included the top 40 principal genetic 
components to account for any remaining population substruc-
ture. Other variables we examined in supplemental analyses of a 
subsample with complete data on all covariates included passive 
smoking, occupational exposure to smoke, antioxidant supple-
ments (vitamin C, vitamin E and β-carotene), social deprivation, 
air pollution (NO2 and PM2.5), waist circumference and liver 
blood tests (alkaline phosphatase, alanine aminotransferase and 
gamma- glutamyl transferase).
Interactions
Studies have reported negative associations with bilirubin and asso-
ciated UGT1A1 genotypes that are strongest in current and heavy 
smokers, which is consistent with endogenous antioxidant proper-
ties.12 29 30 Therefore, we examined interactions with self- reported 
smoking behaviour and categorised participants into never, former 
and current smokers. To examine smoking intensity more closely, 
we further divided smokers who indicated they currently or previ-
ously smoked tobacco on most or all days as ever light- moderate 
smokers (1–19 cigarettes per day) or heavy smokers (20 or more 
Table 5 Associations between genetically predicted serum total 
bilirubin and lung cancer incidence by smoking status in white British 
unrelated participants of UK Biobank
IRR per 5 μmol/L 
increase (95% 
CI) * P value
Estimated incidence 
change in 10,000PYs per 
5 μmol/L increase (95% 
CI) *
Overall 0.90 (0.83 to 0.99) 0.023 −0.76 (−1.42 to −0.10)
Never smokers 0.98 (0.78 to 1.22) 0.87 −0.04 (−0.49 to 0.41)
Former smokers 0.95 (0.84 to 1.08) 0.40 −0.47 (−1.57 to 0.63)
Current smokers 0.83 (0.72 to 0.96) 0.011 −6.44 (−11.45 to −1.44)
Regular smokers (cigarettes per day)
  Overall† 0.89 (0.80 to 0.99) 0.028 −2.08 (−4.00 to −0.16)
  Former 1–19 1.04 (0.81 to 1.33) 0.74 0.31 (−1.57 to 2.20)
  Former ≥20 0.92 (0.79 to 1.08) 0.29 −1.38 (−3.94 to 1.18)
  Current 1–19 0.94 (0.76 to 1.17) 0.57 −2.19 (−9.79 to 5.42)
  Current ≥20 0.72 (0.58 to 0.90) 0.0037 −23.13 (−38.93 to −7.32)
*Adjusted for age, gender, calendar year, ethnicity (first 40 principal components), 
recruitment centre and smoking status. Adjusted and unadjusted incidence rate 
ratios are reported in online supplementary table S1.
†Adjusted for pack- years, age, gender, calendar year, ethnicity (first 40 principal 
components), recruitment centre in overall analysis of regular smokers.
IRR, incidence rate ratio.
Figure 3 Margins of response by smoking status for FEV1 with 95% 
CIs (shaded) at different levels of bilirubin while holding all other 
variables at their observed values. Predictions are for age, gender, 
calendar year, ethnicity (first 40 principal components), height, weight 
and recruitment centre. Non- linear relationships were captured using 
cubic spline transformation with three knots placed at the 10th, 50th 
and 90th percentiles of bilirubin levels.
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cigarettes per day). Pack- years of smoking had previously been 
calculated for participants who smoked tobacco on most or all days 
and also reported their smoking duration.
Statistical analyses
Observational relationships
Serum bilirubin levels were divided into sex- specific quintile 
categories to describe the relationships with other covariates. We 
used multivariable Poisson regression with age as the time scale to 
estimate the lung cancer incidence rate ratios (IRRs) with robust 
SEs per 5 μmol/L increase in serum total bilirubin (entered as a 
continuous variable). We also explored non- linear relationships 
with serum bilirubin and age by applying cubic spline- interpolation 
and selecting the transformation that minimised the Akaike and 
Bayesian information criteria (AIC/BIC). The goodness of fit to the 
Poisson distribution was checked using the deviance statistic and by 
fitting negative binomial models and comparing outputs. We ran an 
overall analysis and then added multiplicative interaction terms to 
derive the smoking- specific IRRs. Multiplicative interaction terms 
on the ratio scale are difficult to interpret for non- linear models 
such as Poisson. Also, the risk of lung cancer varies dramatically 
by smoking status and estimates on the incidence rate (additive) 
scale are also useful for interpretation. We therefore calculated the 
margins of response as adjusted incidence rates and rate differences 
at different levels of bilirubin (1–30 μmol/L) while holding all other 
variables at their observed values. SEs for marginal effects were 
calculated using the delta method. Further details on methods and 
various sensitivity and cross- sectional analyses of potential media-
tors are reported in the online supplementary methods.
Genetically instrumented relationships
We calculated the crude lung cancer incidence rates across geno-
types stratified by smoking status. For the UGT1A1 variant 
(rs887829), we estimated the relationship between homozygosity 
for the T allele linked to Gilbert’s syndrome and lung cancer on 
the rate ratio scale and incidence rate difference scale. We then 
combined the effects of rs887829 and rs4149056 on bilirubin 
levels to estimate the IRRs for lung cancer per 5 μmol/L increase 
genetically predicted bilirubin using one- sample MR and the two‐
stage predictor substitution (2SPS) method.17 Further details are 
reported in the online supplementary methods.
All statistical analyses were conducted using Stata V.16.1 
(Stata Corporation, College Station, Texas, USA) except for the 
exclusion of relatives, which was done using R (V.3.5.1).
RESULTS
After excluding outlier values (n=414), serum total bilirubin 
levels were available for 357 802 participants with a median 
value of 8.1 μmol/L (IQR 6.4–10.4) (table 1). There were 2.5 
million person- years of follow- up, 1917 incident cases of lung 
cancer diagnosed after recruitment, 15 532 deaths from any 
cause and 768 participants were lost to follow- up for various 
reasons including leaving the UK. Men and women with low 
serum bilirubin were heavier, more likely to smoke and live in 
socially deprived areas (table 1). A diagnosis of lung cancer or 
COPD/emphysema prior to recruitment was twice as common 
the lowest bilirubin quintile versus the highest (table 1).
There was a disagreement between the Akaike and Bayesian 
information criteria on the functional form for bilirubin levels 
and we have therefore reported the estimates assuming a linear 
relationship with lung cancer (BIC) and a three- knot cubic spline 
transformation (AIC) (figure 1A and table 2). Assuming a linear 
relationship, each 5 μmol/L increase in adjusted serum bilirubin 
was associated with a 1.2 per 10 000 PY decrease in lung cancer 
(95% CI 0.7 to 1.8) (table 2 and online supplementary table S1). 
The strongest relationships were in current heavy smokers with 
an estimated decrease in lung cancer of 18.4 per 10 000 PY (95% 
CI 3.4 to 33) per 5 μmol/L increase in serum bilirubin (table 2, 
figure 1A and online supplementary table S1). The predicted 
Table 6 Observational and genetically instrumented relationships between bilirubin and FEV1 overall and by smoking status
Number Mean FEV1 (L) Missing FEV1
Adjusted FEV1 (mL) per 5 
μmol/L increase in total 
bilirubin level
FEV1 (mL) per 5 μmol/L increase in 
genetically instrumented bilirubin 
level‡
FEV1 (mL) per 5 μmol/L increase in 
genetically instrumented bilirubin 
level with probability weights for 
missing FEV1‡
Coefficient 
(mL) (95% CI) P value Coefficient (95% CI) P value Coefficient (95% CI) P value
Overall* 377 294 2.85 (0.78) 91 184 (24%) 21 (19 to 24) <0.0001 −0.9 (−1.7 to −0.2) 0.025 −0.4 (−1.4 to 0.2) 0.12
Never smokers 205 211 2.88 (0.78) 50 593 (25%) 18 (15 to 21) <0.0001 −0.6 (−1.6 to 0.3) 0.20 0.3 (−1.3 to 0.7) 0.54
Former smokers 132 709 2.83 (0.76) 30 398 (23%) 22 (18 to 26) <0.0001 −0.7 (−2.0 to 0.6) 0.28 −0.5 (−1.8 to 0.8) 0.45
Current smokers 38 081 2.77 (0.83) 9800 (26%) 46 (37 to 55) <0.0001 −3.5 (−7.5 to −0.6) 0.09 −3.1 (−7.0. to 0.6) 0.12
Prefer not to 
report
1293 2.64 (0.75) 393 (30%)             
Regular smokers†  
  
  Overall 115 247 2.77 (0.78) 26 091 (24%) 36 (32 to 41) <0.0001 −1.3 (−3.0 to −0.4) 0.13 −1.2 (−2.8 to −0.6) 0.21
  Former 1–19 36 606 2.80 (0.76) 8051 (22%) 25 (18 to 33) <0.0001 0.1 (−2.2 to 2.5) 0.68 0.5 (−2.0 to 3.0) 0.68
  Former ≥20 48 296 2.81 (0.77) 11 095 (23%) 33 (26 to 40) <0.0001 −1.4 (−3.9 to 10.4) 0.26 −1.2 (−3.6 to 11.5) 0.31
  Current 1–19 16 032 2.65 (0.80) 4161 (26%) 24 (8 to 40) 0.0003 −4.9 (−11.3 to −14.0) 0.13 −4.7 (−11.3 to −14.2) 0.14
  Current ≥20 10 131 2.64 (0.81) 2784 (28%) 2.4 (−18 to 23) 0.82 −5.2 (−14.8 to 4.5) 0.29 −5.3 (−14.8 to 4.6) 0.29
*Adjusted for age, gender, calendar year, ethnicity (first 40 principal components), recruitment centre, height, weight and smoking status.
†Adjusted for pack- years, age, gender, calendar year, ethnicity (first 40 principal components), height, weight, recruitment centre in overall analysis of regular smokers. 
Participants currently smoking less than one cigarette per day at recruitment are excluded from the smoking subcategories but included in the overall analysis of regular smokers 
if they had formerly smoked one or more per day and it was possible to calculate pack- years.
‡Adjusted for age, gender, calendar year, ethnicity (first 40 principal components), recruitment centre and smoking status.
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incidence using the cubic- spline transformation and adjusting 
for confounders shows that the negative association for smokers 
is steepest at lower bilirubin levels (figure 1A). The independent 
associations between serum bilirubin and lung cancer remained 
after restricting the analysis to participants with a history of 
smoking at least one cigarette per day and adjusting for pack- 
years of smoking (table 2 and online supplementary table S1). 
Based on the predictive margins, the incidence of lung cancer in 
current smokers with a bilirubin level >17 μmol/L (often used 
to diagnose Gilbert’s syndrome) is around 35%–50% lower 
relative to a similar group of smokers in the lowest bilirubin 
quintile (figure 1 and online supplementary table S3). The AIC 
and BIC favoured a three- knot cubic spline transformation of 
bilirubin levels for participants with a history of smoking regu-
larly (figure 1B). Including further covariates for a subset with 
complete data (1666 events) slightly attenuated the relation-
ships (online supplementary figure S1). Serum bilirubin levels 
contributed to all models with spline interpolation (Wald test; 
p<0.0001).
The genetic analysis included 377 294 participants and 2002 
lung cancer events. We confirmed that the selected SNPs were 
strongly associated with bilirubin levels with the UGT1A1 
rs887829 variant explaining 37% (F statistic=57 913) of the 
variability and a non- additive effect of UGT1A1 rs887829 on 
bilirubin levels (table 3). In contrast to observed bilirubin levels 
(table 1), there were no associations between UGT1A1 rs887829 
status and the selected covariates (online supplementary table 
S2). Across most smoking strata, genotypes associated with the 
highest average bilirubin levels were associated with the lowest 
rates of lung cancer, particularly for current smokers (table 3, 
figure 2). In current smokers, the incidence of lung cancer in 
participants with the rs887829 TT genotype linked to Gilbert’s 
syndrome were estimated to be 11.1 per 10 000 PYs lower (95% 
CI 4.1 to 18.1) compared with the other genotypes with the 
association even stronger in current heavy smokers at 38.7 per 
10 000 PYs lower (20.6 to 56.9) (table 4).
The associations between genetically predicted bilirubin and 
lung cancer using the two SNPs was similar, although weaker 
than the observational relationships with levels measured at 
baseline (figure 1, table 5, online supplementary tables S1 and 
S3). The strongest associations were in current heavy smokers 
with each 5 μmol/L increase in genetically predicted serum bili-
rubin associated with a 23.1 per 10 000 PY decrease in incidence 
(95% CI 7.3 to 38.9). Adjusting for covariates made no material 
difference to the MR estimates (online supplementary table S1).
We found weak cross- sectional relationships between raised 
serum bilirubin measured at baseline and higher baseline FEV1 
after adjustment for covariates (table 6, figure 3 and online 
supplementary figure S1). A three- knot cubic spline transforma-
tion was the best fit to the data with a stronger positive relation-
ship at lower values of bilirubin (figure 3). Genetically increased 
bilirubin was associated with a slightly lower FEV1 for most 
smoking categories (table 6). The highest levels of missing data 
for FEV1 were in smokers and people preferring not to declare 
smoking status (table 6). Adding inverse probability weights 
to the regression models to try and account for selection bias 
reduced the strength of the relationship across most smoking 
strata (table 6).
Genetically higher bilirubin was associated with slightly lower 
odds of a family history of lung cancer in smokers and a slightly 
higher odds of COPD overall (online supplementary table S6). 
No observational or causal relationships were evident for the 
negative control cancer outcome (online supplementary table 
S5). There were non- linear relationships for observed serum 
total bilirubin with mortality from any cause (online supplemen-
tary figure S2) with bilirubin levels below 7 μmol/L associated 
with substantially raised rates. There was evidence that genet-
ically increased bilirubin was associated with lower all- cause 
mortality (IRR 0.95 (95% CI 0.91 to 1.0) p=0.034) and cancer 
mortality (IRR 0.92 (95% CI 0.87 to 0.98); p=0.0075) in partic-
ipants with a history of smoking regularly (online supplemen-
tary table S7). The association with cancer mortality weakened 
after excluding lung cancer mortality (IRR 0.96 (95% CI 0.92 
to 0.99); p=0.027). The remaining sensitivity/supplemental 
analyses had no meaningful impact on the overall conclusions 
(supplementary results).
DISCUSSION
In the present study, we confirm earlier reports of a negative 
observational relationship between serum total bilirubin and 
lung cancer that remains after adjustment for smoking pack- 
years and many other variables. We also report for the first time, 
that smokers with genetically raised serum bilirubin levels have 
lower rates of lung cancer and these relationships are strongest 
in current heavy smokers. These findings are potentially consis-
tent with a second- line antioxidant function where raised serum 
bilirubin levels are beneficial once the first- line antioxidant 
defences of the epithelial lining fluid of the lungs are depleted.
Strengths and limitations
The main advantages of the present study are the large sample 
size, the use of a powerful and specific genetic instrument, and 
the longitudinal analysis for lung cancer. The limitations include 
the short length of follow- up, use of self- report for smoking 
status and some other variables. Adjustment for variables such 
as diet, blood counts and cholesterol levels may have further 
attenuated the observational relationships with our primary and 
supplementary outcomes. The lowest predicted level for bili-
rubin was 7 μmol/L and we were unable to determine whether 
the non- linear relationships seen for observed bilirubin, with 
much higher disease/mortality rates at very low levels of bili-
rubin, were potentially causal. The older age at study recruit-
ment and low rates of participation could also be problematic 
in terms of selection bias. The UK Biobank participants tend 
to be taller, leaner and there are fewer smokers relative to the 
UK population.31 Rates of smoking- related diseases are there-
fore reported to be much lower. For example, the prevalence of 
self- reported COPD in UK Biobank is 0.1% in middle- aged men 
versus 1% in the Health Survey for England and lung cancer 
rates are around 50% lower compared with the general popu-
lation.31 Within smokers, heavy smokers are over- represented 
relative to the general population meaning UK Biobank could 
be enriched for ‘resistant’ smokers. Selection bias is a recognised 
problem for UK Biobank and is potentially a problem for our 
study if people with genetically low bilirubin are less likely to 
recruited into UK Biobank due to death or poor health.32 In 
contrast to our findings for lung function, two other studies, 
including a British cohort followed since birth and at lower risk 
of selection bias, reported improved lung function for people 
with alleles linked to Gilbert’s syndrome.29 33 Considering also 
the direction of our MR estimates for COPD and a family history 
of lung cancer, it seems plausible that selection bias could have 
diluted any relationship between genetically raised bilirubin and 
improved respiratory outcomes. The increase in the MR- effect 
estimates for both lung cancer and family history of lung cancer 
as smoking levels increased is reassuring against chance findings, 
although some of the smoking specific strata have few events 
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and replicating our results in similarly large cohorts is desirable. 
Finally, horizontal pleiotropy, whereby another substrate is the 
real causal agent, is a possibility particularly given the position of 
UGT1A1 in a gene complex expressing nine other isoforms with 
different and overlapping substrates for glucuronidation. Known 
phenotypes for the low activity SNPs we selected are toxicity 
to irinotecan chemotherapy (UGT1A1) and statin therapy 
(SLCO1B1) but these seem unlikely to explain our results. We 
can find no other reductions in substrate elimination that could 
explain the observed relationships with lung cancer.24
Comparison with other studies
Several large cohorts have reported observational relationships 
between bilirubin and lung cancer. A recent global metabolomic 
profiling approach in ‘Caucasian’ lung cancer cases and controls 
identified bilirubin from 403 known metabolites as one of the 
only consistently significant biomarkers.30 The same study vali-
dated this finding in a large cohort of 425 660 Taiwanese adults. 
They reported significant effect modification by smoking status, 
and for every 0.1 mg/dL (1.71 µmol/L in standard international 
units) increase of bilirubin, the risks for lung cancer incidence 
and mortality decreased by 5% and 6% in male smokers, respec-
tively (both p<0.001). There was no association in women 
possibly due to fewer smokers and cancer events. A similarly 
large cohort of British adults (n=504 206) reported an 8% 
decrease for every 0.1 mg/dL (1.71 µmol/L) increase in serum 
bilirubin levels in men (p<0.001).11 The relationship was consis-
tent across genders and no effect modification by smoking was 
detected (p for interaction >0.05). A third recent study reported 
a negative relationship with lung cancer with rates 50% lower 
in the higher serum bilirubin quintile (>11 µmol/L) but this was 
not statistically significant.13 We have now shown that these rela-
tionships with serum bilirubin remain in regular smokers after 
adjusting for additional variables not always accounted for in 
the earlier analyses including pack- years, passive smoking, occu-
pational smoke exposure and air quality. At this time, we are not 
aware of any other large- scale prospective studies of UGT1A1 
variation and lung cancer specifically. Several studies have exam-
ined the relationship between genetically predicted bilirubin 
and other clinical outcomes with mixed results that possibly 
reflects differences in the pathophysiological role for oxidative 
stress, smoking case- mix, age at recruitment, low power for 
rare outcomes and study design.34 35 Genome- wide association 
studies have not identified the UGT1A1 locus in studies of lung 
cancer, although the number of smokers required to reach the 
high threshold for genome- wide statistical significance exceeds 
that available in most cohorts.
Future directions
Our findings support further studies on the utility of serum 
bilirubin as a low- cost biomarker for lung cancer risk stratifi-
cation.12 20 Accurate risk stratification is key to the clinical 
and cost- effectiveness of low- dose CT screening programmes 
being adopted in the USA and piloted in the UK.2 Given the 
high frequency of lung cancer and the high- cost of false positive 
results of CT- screening for the patient and provider, even a small 
improvement in risk prediction could have a meaningful impact 
and is worth exploring. Further preclinical work could examine 
whether competitive inhibitors of the UGT1A1 enzyme are legit-
imate drug targets.
Gilbert’s syndrome is a common condition characterised by 
moderately elevated levels of unconjugated bilirubin and intermit-
tent episodes of jaundice. Ten per cent of people with European 
or East Asian ancestry and 25% of people with equatorial African 
descent have at least two functional variants of UGT1A1 asso-
ciated with the condition, although not all will meet the bili-
rubin threshold for diagnosing Gilbert’s syndrome.3 36 The high 
frequency of different UGT1A1 variants causing mild hereditary 
hyperbilirubinaemia has led to speculation of balancing natural 
selection whereby physiological benefits of hyperbilirubinaemia 
are countered by the neurotoxic impact on infants. Under this 
scenario, functional alleles reach a high frequency but never 
fixate.3 Our results suggest that for UK Biobank participants self- 
reporting as current smokers and with a phenotype consistent with 
Gilbert’s syndrome (serum total bilirubin >17 μmol/L), rates of 
lung cancer are 35%–50% lower and mortality 20%–40% lower 
than a similar group of smokers with bilirubin levels <5 μmol/L. 
Protection against smoke oxidants could have been advantageous 
for early humans once fire was discovered and widely used for 
lighting, warmth, cooking in poorly ventilated caves or dwell-
ings.37 However, protection against infectious diseases is strongly 
implicated as the primary driver of existing examples of balancing 
selection and raised serum bilirubin does seem to inhibit conta-
gious agents including group B streptococcus,38 hepatitis C39 and 
malaria parasites.40 As more events accrue in UK Biobank and the 
data become fully linked with primary healthcare records, it will 
be feasible to investigate a role for serum bilirubin in other infec-
tious and non- communicable diseases.
Summary
We have shown that adult smokers in UK Biobank with geneti-
cally raised bilirubin have lower rates of lung cancer, supporting 
endogenous antioxidant properties. Further work is required to 
establish whether bilirubin is a useful low- cost biomarker for 
improving risk prediction and a legitimate therapeutic target for 
disease prevention.
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